Press Release

Emerson Ecologics Selected as a Distribution Partner for ProThera® Nutraceuticals
Press Release
Written by Christine DeLong   
Tuesday, 25 February 2014 12:06
MANCHESTER, NH, February 24, 2014 ‐‐ Emerson Ecologics, LLC, the leading provider of the highest quality professional nutritional supplements to healthcare practitioners and their patients for over 30 years, today announced their expanded strategic partnership with ProThera, Inc., an integrated nutraceuticals company for healthcare professionals. Effective today, February 24, 2014, ProThera® brand products will be available to Emerson Ecologics practitioner customers throughout the United States. Although ProThera’s Klaire Labs® brand has been available to Emerson customers for many years, ProThera® brand products were only available in the US through ProThera, Inc. until now. While ProThera’s direct distribution of its ProThera® and Klaire Labs® brands to healthcare professionals will not change, ProThera’s decision to partner with Emerson Ecologics will allow expanded reach to complement their strong direct to practitioner business.
ProThera, Inc. develops and sells an integrated selection of nutraceuticals to healthcare professionals, including its ProThera® and Klaire Labs® product lines. The ProThera® line is differentiated by an integrated approach to formulation that maximizes synergism between nutrients to avoid nutrient redundancy, maintain cost-effectiveness, and encourage patient compliance. It offers versatile multiple vitamin/mineral supplements including MultiThera® and VitaPrime® complemented by focused multinutrient and single ingredient formulas to target patient needs while using fewer pills at lower cost. Its Klaire Labs® line is well known for hypoallergenic probiotics, enzymes, and specialty nutraceuticals.

Emerson Ecologics CEO, Andy Greenawalt remarked, “We are excited to have been selected as a US distribution partner for ProThera®. Their commitment to quality is aligned with Emerson’s objective to provide practitioners and their patients access to the safest and most effective products. We look forward to the opportunity to educate our customers on the ProThera® brand and collaborating with ProThera to expand their reach.”
“Our commitment to providing healthcare professionals with access to clinically relevant supplement formulations coupled with prompt, personalized attention has always been our top priority,” stated ProThera President & CEO, Dennis Meiss, PhD. “Offering expanded access to both ProThera® and Klaire Labs® brands through an alliance with Emerson Ecologics furthers that goal.”
Emerson Ecologics offers the complete line of current ProThera healthcare practitioner products at the same price as direct through ProThera. Additionally, Emerson carries thousands of products, enabling practitioners to save valuable time and money by selecting from over 275 brands in a single order.
Orders can be placed online 24 hours a day at or by phone at 800.654.4432 from 8:30 am-8:00 pm ET.

About Emerson Ecologics
Founded in 1980, Emerson Ecologics, LLC is the leading distributor of professional-quality nutritional supplements, vitamins and natural health products—representing over 275 brands. Customers include integrative healthcare practitioners, naturopathic, chiropractic and medical doctors, licensed acupuncturists, and nutritionists, as well as their patients. Widely-recognized for their innovative Emerson Quality ProgramSM (EQP), EQP Partners are verified to be compliant with FDA Dietary Supplement cGMP standards to help ensure the safety of supplements. Headquartered in Manchester, NH with distribution centers in Virginia and California, Emerson Ecologics is GMP registered by NSF® International. For more information, visit

About ProThera, Inc.
ProThera, Inc. is a Reno, NV-based manufacturer of ProThera® and Klaire Labs® brand dietary supplements. Stringent research, manufacturing and delivery processes ensure product potency and viability, making them the nutritional supplements of choice for discerning healthcare professionals around the world. ProThera, Inc. operates a GMP 9000 registered facility certified by NSF® International. For more information about the company, visit

Christine DeLong
Emerson Ecologics
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
# # #
ChiroTouch to Host “2014 EHR: The Year You Can’t Hide From!” Webinar
Press Release
Written by Robert Moberg   
Friday, 21 February 2014 13:46
San Diego, CA – February 21st, 2014 – ChiroTouch™, the nation’s leader in chiropractic software, is pleased to announce the “2014 EHR: The Year You Can’t Hide From!” webinar, which is scheduled to air live for one hour on February 27th, 2014, at 10:00am PST.

“The EHR rules have changed, which means doctors must show meaningful use by October of this year,” said Robert Moberg, President of ChiroTouch.  “That date will be here before we know it, so we’ve created this webinar to ensure that our family of doctors is informed and able to navigate the road ahead.”

With Medicare, EHR Stimulus Requirements, PQRS, and ICD-10s, 2014 is not like any other year! Did you know that the Medicare EHR program has been updated? Are you aware of the new deadlines?  Join us for an informative session designed to provide you with REAL info to gain a REAL understanding on the changes, requirements, and deadlines that will affect ALL of chiropractic in 2014.

Don’t miss this special session with our guest Dr. Gary Street, who will be speaking on PQRS.

Other recent webinar topics include “Chiropractic and ICD-10: How to Make the Transition,” “Financial Tips That Can Improve Your Finances Now,” and “Most Proven Ways to Stay Excited about Practice.”  The ChiroTouch webinar programs and the attendees have benefited from speakers such as Dr. Miles Bodzin, Dr. Billy DeMoss, Dr. Brad Glowaki, Garrett Gunderson, Dr. Ron Oberstein, Dr. Eric Plasker, Rick Sapio, and many more.  This cross-section of the most influential and recognized coaches and speakers has made for a very robust and popular series of webinars.

To join ChiroTouch this webinar, visit

About ChiroTouch ChiroTouch, by Integrated Practice Solutions Inc., is the premier provider of fully-certified innovative chiropractic software technology solutions for the chiropractic industry. Fusing advanced software systems with superior support services, we partner with chiropractors across the country to help them automate operations, improve patient care, and increase profitability.  Visit

Biotics Research Launches Gluten-Free Awareness Campaign
Press Release
Written by Debra Fish   
Friday, 21 February 2014 13:44
Rosenberg, TX – February 20th, 2014 – Biotics Research Corporation, the industry leader in the development of superior, gluten-free nutritional supplements, has launched a full campaign to bring awareness to both healthcare providers and patients on the importance of gluten-free nutritional supplements.

“With such a large percentage of the population sensitive to gluten on some level, it’s imperative that patients take supplements that are free of gluten,” explained Denis DeLuca, President of Biotics Research. “We understand the challenges those with a gluten sensitivity face when trying to maintain a gluten-free diet, which is why we’ve taken great care to ensure that all of our products are gluten-free.”

Research shows that as many as 10 percent of the U.S. population has some level of gluten sensitivity. Gluten is problematic for those with gluten sensitivity because it inhibits the body’s ability to absorb nutrients and defend against would-be pathogens. The detrimental impact of gluten on the body for those with gluten sensitivity results in a variety of symptoms, including bloating, abdominal discomfort, pain, diarrhea, headaches and migraines, lethargy, attention-deficit disorder, muscular disturbances, bone and joint pain, among others. Given that gluten is ubiquitous in the standard American diet, eliminating it can be a challenge.

People with gluten sensitivity often fail to consider whether their supplements contain gluten. Biotics Research has taken the guesswork for both providers and patients from having to choose the right supplements as its entire catalog of almost 300 products are gluten free – and they always have been!

Biotics Research is creating print and online marketing and educational materials in its efforts to bring awareness to both practitioners and patients.

“More and more people are learning that many of the symptoms they’ve been having for years are a result of some level of gluten sensitivity,” added Denis. “And we understand that eliminating gluten from a diet can be a difficult challenge. Our gluten-free supplements are the perfect solution because those with gluten sensitivity no longer have to worry about whether the supplements they’re taking to try to improve and support their health could in fact be hindering it.”

To learn more about Biotics Research Corporation and its gluten-free catalog of supplements, please visit or download the Biotics Research Mobile App at the Apple® App Store or Google® Play Store.

About Biotics Research Corporation
Biotics Research Corporation has been a leading manufacturer of specially designed, gluten-free nutritional supplements for nearly forty years. Our mission remains constant: to be the benchmark of excellence in nutritional science, technology and service, providing the clinician and their patients with reliable, innovative products of superior quality. Visit
Douglas Laboratories® Launches New Star Product, Sereniten Plus™
User Rating: / 1
Press Release
Written by TAC Staff   
Thursday, 13 February 2014 15:23
Stress management and cortisol regulation support formula now available throughout North America

PITTSBURGH, Pa., February 11, 2014Douglas Laboratories®, the trusted choice of healthcare professionals for superior quality, science-based nutritional supplements for more than 50 years, is proud to announce the addition of Sereniten Plus™, to its existing line of products available in the United States. Developed by Penny Kendall-Reed, N.D., a specialist in metabolic disorders who is also a member of the Douglas Laboratories® Clinical Advisory Board, Sereniten Plus™ rapidly became a popular stress management support choice for Canadian healthcare practitioners.

sereniten-plus“Douglas Laboratories Canada has had great success partnering with Dr. Kendall-Reed to educate and promote Sereniten Plus in 2012 and 2013. This product, now available throughout North America, is the most successful new product launch to date,” said Andrew Halpner Ph.D., Vice President, Product Development and Technical Services at Douglas Laboratories.

“Sereniten Plus was developed to promote an anxiolytic effect - supporting mental and physical stress,”† said Dr. Kendall-Reed. “Lactium® is the only supplemental ingredient I have found to lower glucocorticoid secretion and rebalance the Hypothalamic-Pituitary-Adrenal pathway.”†

The Sereniten Plus™ formula consists of a combination of Lactium®, L-Theanine and Vitamin D to support the HPA axis and feedback loop for stress management and cortisol regulation. Lactium®, a bioactive decapeptide, and L-Theanine have been shown to provide a calming effect without drowsiness and support normal sleep that is affected by stress.† It is also unique in how it increases the sensitivity of the hypothalamus to cortisol, thereby re-establishing the receptor sensitivity and feedback within the HPA axis.

Results from studies have shown that 30 days of supplementation with Lactium® can result in lowered plasma cortisol levels and a reduction in stress related issues promoting digestion, cardiovascular, intellectual, emotional, and social wellbeing. †

Douglas Laboratories will host an educational webinar for healthcare professionals, presented by Penny Kendall-Reed, N.D., on February 12, 2014,and titled “Why Diets Fail - A Neuroendocrine Approach to Weight Loss.” To register for the webinar, or for further information on the Douglas Laboratories® Sereniten Plus™ formula, please visit

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.

A business unit of Atrium Innovations Inc. (TSX: ATB & ATB.DB), Douglas Laboratories®, the trusted choice of thousands of healthcare professionals for over 50 years, is proudly researching, developing and manufacturing superior quality, science-based supplements that help people improve their health. Douglas Laboratories provides added insurance of multiple domestic and international GMP certifications, including ISO-9001 Certification and ISO-17025 accreditation for in-house laboratories, as well as NSF International Registration. With its headquarters located in Pittsburgh, Pennsylvania, USA, Douglas Laboratories currently offers over 600 branded products distributed worldwide. For additional information, please visit

Penny Kendall-Reed is a Naturopathic Doctor in Toronto.  After graduating from McGill University with a B.Sc. in Neurobiology, she attended the Canadian College of Naturopathic Medicine, where she earned her degree in Naturopathic Medicine and received the Dr. Allen Tyler Award for Most Outstanding Clinician.  As a specialist in metabolic disorders and author of a national best sellers, The Naturopathic Diet, and The New Naturopathic Diet, and co-author, The No Crave Diet, Healing Arthritis, The Complete Doctor’s Healthy Back Bible and The Complete Doctor’s Stress Solution Penny Kendall-Reed lectures throughout Canada and the United States.  She holds health retreats and lectures at various resorts worldwide, and appears regularly on television, magazine and radio across Canada and the United States addressing various health issues.  Penny Kendall-Reed has also designed an all natural oral and topical anti-aging skin care line called Age Aware Skin Care sold throughout the UK.  Presently, Penny Kendall-Reed is the director of natural therapies at the Urban Wellness Clinic in Toronto.

Atrium Innovations Inc. (TSX: ATB & ATB.DB) is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products which are distributed in more than 35 countries.  The Company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education.  Atrium has over 1,300 employees and operates seven manufacturing facilities complying with current Good Manufacturing Practices. Additional information is available at
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments
Press Release
Written by TAC Staff   
Thursday, 13 February 2014 11:04
Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Brain, Bladder and Prostate Cancers

Toronto, Ontario – February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25). 

“The ability for the PDC technology to be effective in low oxygen environments is considered to be an essential factor in the recurrence and progression of non-muscle invasive bladder cancer. This form of disease represents up to 75% of newly diagnosed bladder cancer cases accounting for more than 386,000 cases and 150,000 deaths annually worldwide,” said Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. Dr. Mandel continued: “The abnormal decrease or the lack of oxygen supply to cells and tissues is called hypoxia and commonly presents in solid cancers, such as brain, bladder, breast, lung and prostate. Hypoxic cancers are extremely aggressive, resistant to standard therapies (chemotherapy and radiotherapy), and thus very difficult to destroy. Tumor hypoxia is known to play a role in cancer metastasis (spread) and resistance to therapy, as well as the ability of cancer cells to escape destruction by the immune system. The evidence supporting the Theralase PDC technology represents a potential solution for hypoxic cancers. In our work, we described a family of Theralase PDCs that have shown an ability to switch their photoreactivity from a Type II reaction (oxygen dependent) to a Type I (free radical mediated) reaction. This is strategic to the Company in that a Type I reaction is unique and opens the opportunity of using the PDCs beyond sterilization and the treatment of superficial cancerous lesions to the treatment of harder to treat tumours”.

Dr. Lothar Lilge, Senior Scientist  at the Princess Margaret Cancer Centre, University Health Network stated that, “In well oxygenated environments, these new PDCs generate singlet oxygen, a dominant cytotoxic substance with close to 100% efficacy, yet under hypoxia (low oxygen) conditions, they display the remarkable ability to switch to a Type I or oxygen independent cytotoxic substance owing to their ability to simultaneously act as an excited state oxidant and reductant. The intrinsic positive charge of the Ru(II) metal combined with the oxygen independent light activated cytotoxicity demonstrated by this family of PDCs opens a new strategy for destroying both gram-positive and gram-negative bacteria regardless of oxygenation level.  Therefore, this has a significant impact on the destruction of cancer cells by PDC technology, as a considerable fraction of cancer will survive in low oxygen environments and according to the literature this is one of the causes for recurrence of cancer post therapy.” 

Dr. Michael Jewett, Clinical Principal Scientific Investigator at Princess Margaret Cancer Centre, University Health Network and University of Toronto stated that, “I am extremely encouraged by the results of this scientific work and the implications that it may have in the destruction of bladder Transitional Cell Carcinoma, as the bladder is traditionally known as a very low oxygen environment. There has not been a new drug approved for bladder cancer since 1998 and I am looking forward to working with the Theralase team to initiate a Phase 1 / 2 clinical trial in 1Q2015.”

About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in healing injured tissue and destroying cancer.  Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint injuries. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated. 

Additional information is available at and 
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:
Roger Dumoulin-White,  
President & CEO
416-699-LASE (5273) ext. 225
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Page 16 of 37
TAC Cover
TCA Cover
BL Cover
Buyers Guide

Click on image above
to view the
Digital Edition






TAC Publications

The American Chiropractor Magazine: Digital Issues | Past Issues | Buyer's Guide


More Information

TAC Editorial: About | Circulation | Contact

Sales: Advertising | Subscriptions | Media Kit